Objective: To evaluate the anti-fibrotic effects of Astragaloside IV in systemic sclerosis. Methods: Treated or untreated systemic sclerosis (SSc) and normal fibroblast isolated from corresponding pairs were utilized to detect expression of collagen and fibronectin by western blot, quantitative real-time RT-PCR (RT-qPCR), immunofluorescence staining and histopathological examination. SSc mouse model induced by bleomycin was used to evaluate the effects of the drug in vivo.
Introduction
Systemic sclerosis (SSc) is a complex, heterogeneous, autoimmune connective tissue disease characterized by excessive fibrosis of the skin lesions and internal organs due to fibroblast proliferation and excessive production of the extracellular matrix (ECM) [1] . The disease has two major sub-groups, classified as limited cutaneous scleroderma (lSSc), and
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry male donors with circumcision surgery who were matched with the SSc patients for age, sex, and race (Table  1) . SSc and normal fibroblast pairs were utilized at passages 4-6 for all experiments.
Bleomycin-induced skin fibrosis mice model and Astragaloside IV treatment
6-8-week-old female specific pathogen-free (SPF) C57/BL6 mice were supplied by the Laboratory Animal Center of Sun Yat-sen University. The animals were allowed free access to water and standard mouse chow and housed at 25°C with 40% humidity and with a 12h/12h light/dark cycle. The mice were randomly divided into three groups: the control group, the model group, and the Astragaloside IV (AS-IV, Sigma) (2.0 and 4.0mg/kg) treatment groups (n= 6 mice per group). To establish the skin fibrosis model, bleomycin (Sigma) was diluted to 0.1 U/ml with PBS, and filter sterilized. 100μl of bleomycin (for model group and AS-IV treatment group) or PBS (for normal group) was injected subcutaneously into a single location on the shaved back of mice once daily for 4 weeks, in accordance with a previous study [19] . To evaluate the effect of Astragaloside IV in vivo, AS-IV solution was prepared by ultrasonication in 0.5% sodium carboxymethylcellulose (CMC-Na) solution. AS-IV was administered to AS-IV treatment group by gavage once daily for 4 weeks. The same volume of vehicle was given to the normal group and model group as controls. Mice were sacrificed -humanely using CO 2 , and the lesional skin was collected for further analysis.
Protein extraction and immunoblotting
The procedures were performed as previously described [20] . In brief, skin samples from the injection site of the animals were homogenized and lysed in lysis buffer containing 7mol/L urea, 2mol/L thiourea, 2% CHAPS, 0.1mol/L DTT, 0.1% NP40, and 40mmol/L Tris-HCl using a Polytron homogenizer, followed by centrifugation (100,000g) for 30min at 4°C. For the cultured cells, the lysates were harvested by centrifugation (12,000g) at 4°C for 15min. The supernatants were separated, and protein concentration was assessed using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, United States). After incubation at 100°C for 10min, equal amounts of denatured protein were resolved on a SDS-PAGE and were electrophoretically transferred onto PVDF membranes. The blots were probed with primary antibodies, including anti-collagen, anti-Fli-1 and anti-Fibronectin (Santa cruz, Biotechnology, CA, United States); anti-SMAD3 and anti-p-SMAD3 (Cell Signaling Technology, Beverly, MA, United States). After washing, appropriate horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) were used for detection with the ECL and ECL-plus systems (Forevergen Biosciences, Guangzhou, China). On completion, the membranes were stripped and probed with a β-actin antibody (Cell Signaling Technology), which served as a loading control. The intensity was quantitated by densitometry.
Quantitative real-time RT-PCR (RT-qPCR)
The procedure was slightly modified in accordance with previous studies [21, 22] . Total RNA was extracted using TRIzol reagent (Gibco, Grand Island, NY, United States). Total RNA (5μg) was treated with 
Immunofluorescence staining
Procedures were in accordance with previous protocols [23] . Cells cultured in chamber slides (Thermo Fisher Scientific, Waltham, MA, United States) were washed, fixed, and permeabilized. The cells were then incubated with rabbit anti-human collagen I antibody (1:50 dilution), or rabbit anti-human fibronectin antibody (1:25 dilution; Novus Biologicals, Littleton, CO, United States). Subsequently, the cells were incubated with fluorescent secondary antibody Alexa Fluor® 488 Donkey Anti-Rabbit IgG (Invitrogen, Carlsbad, CA, United States), then counterstained with Hoechst 33258 (Invitrogen) for nuclei staining. They were inspected and photographed using fluorescence microscopy (Olympus BX51W1, Tokyo, Japan). Fluorescent positive rates were counted in five randomly selected areas and analyzed independently by three reviewers.
Histopathological examination
Lesion skin tissues were fixed overnight with 10% formalin, dehydrated, and embedded in paraffin using standard techniques [24] . Consecutive 5μm serial sections were cut and stained with hematoxylin and eosin (H&E). To determine the collagen content and organization of the lesional skin, deparaffinized sections were processed for Masson's trichrome stain according to the manufacturer's instructions.
Statistical Analysis SPSS version 13.0 (SPSS Inc., Chicago, IL) was used for data analysis. Continuous variables with normal distribution are presented as the mean±standard deviation (Mean±SD). Significance was defined as P < 0.05.
Results

Inhibition of collagen and fibronectin expression by Astragaloside IV in SSc fibroblasts
Fibroblasts from normal (NF) and SSc (SScF) samples were treated with Astragaloside IV (AST) in a variety of doses and durations, followed by western blot and RT-qPCR assays. Compared to normal fibroblasts, the expression of collagen and fibronectin in SSc dramatically increased. When treated with Astragaloside IV, the expression level was decreased in a dose- (Fig 1 A) and time-dependent manner (Fig. 1 B) . The expression of collagen and fibronectin in SSc fibroblast shown decreases after treatment with Astragaloside IV in the dose of 30μM for 72h (Fig 2) . The mRNA level of collagen and fibronectin were consistently significantly higher in SSc fibroblasts than in normal fibroblasts. Treatment with Astragaloside IV suppressed Collagen I α2 (COL I α2) and fibronectin mRNA expression in a similar fashion (Fig. 1 C, 1 D) . These data suggest that Astragaloside IV has an inhibitory effect on collagen and fibronectin expression in SSc fibroblasts.
Astragaloside IV decrease fibronectin in SSc fibroblasts
Fibronectin is assembled into the extracellular matrix, and is involved in cell adhesion, growth, migration, and differentiation. Staining fibronectin helps to define fibroblast function. Thus, we utilized immunofluorescence staining to observe the formation of fibronectin. As
was observed in SSc fibroblasts, which decreased and decomposed into diffusion with the treatment of Astragaloside IV.
Inhibition of fibrosis by Astragaloside IV in SSc mouse model
To test the anti-fibrosis effects of Astragaloside IV in vivo, SSc model mice induced by bleomycin were treated with Astragaloside IV. Lesion skin tissues were subjected to Masson's trichrome as well as H&E staining. Masson's trichrome is a three-color staining protocol used in histology which produces red keratin and muscle fibers, blue or green collagen and bone, light red or pink cytoplasm, and dark brown to black cell nuclei. As shown in Fig. 3A , normal skin staining exhibited clear layers of epidermis and dermis, with abundant adipocytes in the hypodermis. In contrast, SSc lesion skin displayed massive green collagen staining and abnormal histology structure. Administration of Astragaloside IV decreased the collagen formation as well as partially restored the structure, in a dose-dependent fashion.
Delivery of Astragaloside IV decreased expression of collagen and fibronectin in vivo
To further confirm that the expression of collagen and fibronectin in vivo was reduced, lesion tissues were subjected to western blot and RT-qPCR assays. Consistent with the aforementioned staining results, Collagen I and Fibronectin expression was significantly higher in SSc model samples compared with control, which was in turn attenuated by treatment with Astragaloside IV in dose-dependent manner at both protein (Fig.3B) and mRNA (Fig. 3C ) levels.
Astragaloside IV-induced fibrosis reduction is due to deregulation of Smad3/Fli-1
To elucidate the underlying mechanism of Astragaloside IV-induced fibrosis reduction, Smad3/Fli-1 expression, which functions as a mediator of the fibrotic response and comprises key molecules for TGF-β signaling, was evaluated. As expected, phosphorylation of Smad3 was suppressed by Astragaloside IV in dose-and time-dependent manner in SSc 
Astragaloside IV regulated Smad3 activity and localization
To further confirm the inhibitory effect of Astragaloside IV on TGF-β-Smad pathway, we investigated the activity and localization of Smad3 upon drug treatment. As shown in Fig. 4E , phosphorylated Smad3 (p-SMAD3), which was in activated form in the pathway, was significantly higher in SSc fibroblasts (SScF) compared to normal fibroblasts (NF). Interestingly, treatment with Astragaloside IV not only decreased the level of p-SMAD3, but also completely blocked its relocation into the nucleus where it interacts with other cofactors to activate TGF-β-dependent gene transcription. 
Discussion
This study is the first, to our knowledge, to report the anti-fibrotic role of Astragaloside IV in systemic sclerosis (SSc) in vitro and in vivo models.
SSc is a complex multi-organ system group of diseases of unknown causative factor [25] . Characteristic features include vasculopathy and excessive collagen accumulation in skin and internal organs [26] . Fibrosis, whereby the deposition of collagen and other components ultimately replaces the normal architecture of blood vessels, internal organs and skin, is considered to be the hallmark of SSc [27, 28] . Indeed, we isolated SSc fibroblasts from patients and found that expressed levels of collagen and fibronectin, which indicate fibrosis, were significantly higher. Later, in lesional skin samples from SSc model mice, we not only confirmed the increased expression of collagen and fibronectin, but also observed a disordered histology structure. These changes lead to induration, or thickening of the skin, which is the classic clinical symptom [26] . However, the pathogenesis of SSc, despite significant recent developments by dedicated translational scientists, remains largely unknown [29] .
Interestingly, Astragaloside IV, one of the most active compounds isolated from a Chinese medical herb [30] , could decrease the expression of collagen and fibronectin in a dose-and time-dependent manner. Further, this drug displayed a strong anti-fibrosis effect in vivo, consistent with previous studies [10, 11, 15, 16] . Recent studies also suggest that Astragaloside IV has broad application prospects, especially in cardiovascular diseases, digestive diseases, cancer, and other modern high-incidence, high-risk diseases [31] . Nevertheless, the molecular mechanisms of the action of Astragaloside IV are still not clear. Increasing evidence suggests that TGF-β plays a key role in the development of SSc [32] . Overexpression of TGF-β-dependent genes has also been found in biopsy specimens from patients with SSc. Upregulation of the TGF-β-Smad signaling pathway has been described [33] . TGF-β stimulates fibroblast proliferation, differentiation, and cytokine secretion [34] . It promotes the upregulation of collagen synthesis and the accumulation of extracellular matrix (ECM) [35] . TGF-β binds to its receptor and activates the signaling leading to phosphorylation of transcription factors Smad2 or Smad3. Phosphorylated Smad2 or Smad3 bind to Smad4, the common Smad, and the resulting complex moves from the cytoplasm into the nucleus [36] . In the nucleus, the Smad complex interacts with various other transcription factors and then transactivates fibrosis-associated genes such as type I collagen and fibronectin [33] . Consistent with these findings, we demonstrated that Astragaloside IV regulated the expression of Smad3/Fli-1, major mediators of the fibrotic response and key molecules for TGF-β signaling. Furthermore, Astragaloside IV decreased the level of phosphorylated Smad3 and completely blocked its relocation into the nucleus, where it interacts with other co-factors to activate TGF-β-dependent gene transcription [37] . Studies suggest that Smad4 interaction with specific transcriptional factors including Sp1, which plays an essential role in the stimulation of collagen transcription in normal fibroblasts, may account for the pro-fibrotic state in SSc [38] . In addition, evidence shows that increased levels of Smad2/3 phosphorylation may be explained by decreased levels of the inhibitory Smad7 in SSc [39] . It would be helpful to illustrate whether Astragaloside IV treatment affects these activating or inhibitory factors in future studies. Intriguingly, Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy [40] . Thus, another field that requires more exploration may be the combination effect of Astragaloside IV with conventional agents for SSc treatment. One of the limitations of this study is that as well as TGF-β-Smad signaling, Astragaloside IV may also target other pathways related to SSc, since at least 39 putative targets have been identified by Zhao and his colleagues [41] . Their results suggest that the therapeutic effects of Astragaloside IV are based upon a combination of blocking calcium influx, vasodilation, anti-thrombosis, anti-oxidation, antiinflammation and immune regulation.
In China, treating scleroderma using the prescription for nourishing the kidney and strengthening the essence in traditional Chinese herbal medicine has a long history
